PTK/ZK (Novartis)

IDrugs. 2003 Aug;6(8):787-94.

Abstract

PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / chemical synthesis
  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Phthalazines / adverse effects
  • Phthalazines / chemical synthesis
  • Phthalazines / pharmacology*
  • Phthalazines / therapeutic use
  • Pyridines*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Phthalazines
  • Pyridines
  • vatalanib
  • Receptors, Vascular Endothelial Growth Factor